Do you offer consolidation durvalumab in stage III patients with NSCLC who developed grade 2 radiation pneumonitis during chemoradiation?

The cleanest answer is no, I would not put a patient on durvalumab who experienced pneumonitis during radiation. This is in keeping with the clinical protocol for the PACIFIC trial which excluded patients who experienced any grade pneumonitis during radiation (including grade 1). The reason we now obtain post chemoradiation CT's within a few weeks of completing radiation is in part because of this exclusion criteria. I think the issue moving forward is whether patients with grade 1 toxicity ie radiographic findings only may be safely treated with very close monitoring. Since they were excluded from the study we do not have a good answer here. There are excellent answers from Dr. @Dr. First Last (https://www.themednet.org/question/5172) abou...